Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. Based on the Canopy Growth Corporation stock forecasts from 15 analysts, the average analyst target price for Canopy Growth Corporation is USD 8.23 over the next 12 months. Canopy Growth Corporation’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Canopy Growth Corporation is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Canopy Growth Corporation’s stock price was USD 4.97. Canopy Growth Corporation’s stock price has changed by +4.41% over the past week, -12.96% over the past month and -80.95% over the last year.

1. Page 1 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
CGC:NSD (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | NSD | Common Stock
Values as of 31st May, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 1st June, 2022
Last Close
USD 4.97
Change
+0.09(+1.84%)
Market Cap
USD 1.95B
1 Yr Capital Gain
-79.53%
1 Yr Dividend Return
N/A
1 Yr Total Return
-79.53%
Earning Growth (5 yr)
-1,719.60%
Average Target Price
8.23(+65.59% )
Average Analyst
Rating
Under-perform
Fundamental
Analysis
Bearish
Our view of the stock is Bearish with a score of 2.9 out of 10, where 0 is very bearish and 10 very bullish
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to
make sure there is no specific reason.
What to not like
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector

2. Page 2 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
CGC:NSD (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 1st June, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
CGC
Canopy Growth Corporation
-81% 0 -81%
QQQ
Invesco QQQ Trust Series 1
-7.7% +0.4% -7.3%
Company Overview
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based
products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments,
Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel
capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel,
DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a
strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical
research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the
mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to
Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

3. Page 3 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.canopygrowth.com
Address
1 Hershey Drive, Smiths Falls, ON, Canada, K7A 0A8
Fiscal Year End
March
Technical Indicators
Value Value
Beta 1.98 52 Week High 26.96
Short Ratio 8.34 52 Week Low 4.60
Shorted Shares 50,012,347 200 Day Moving Average 10.06
Shorted Shares Previous Month 54,422,269 50 Day Moving Average 6.31
Shares Held By Insiders 3,541.50% Short Percentage 8.00%
Shares Held by Institutions 17.44 Dividend Yield N/A

4. Page 4 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
CGC:NSD (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 1st June, 2022
Market Performance
Market Performance vs. Industry / Classification (Drug Manufacturers-Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain -43.07% -43.1% 49% -17.3% 27%
Dividend Return N/A 8.4% N/A 0.9% N/A
Total Return -43.07% -43.1% 49% -16.9% 27%
Trailing 12 Months
Capital Gain -79.53% -69.1% 35% -19.9% 12%
Dividend Return N/A 12.0% N/A 2.2% N/A
Total Return -79.53% -69.1% 35% -18.7% 12%
Trailing 5 Years
Capital Gain N/A -69.8% N/A 7.5% N/A
Dividend Return N/A N/A N/A 11.0% N/A
Total Return N/A -69.8% N/A 18.0% N/A
Average Annual (5 Year Horizon)
Capital Gain -11.62% -3.2% 35% 2.6% 14%
Dividend Return N/A 4.3% N/A 1.8% N/A
Total Return -11.62% -3.2% 35% 4.5% 14%
Risk Return Profile
Volatility (Standard
Deviation)
51.08% 46.4% 44% 32.2% 29%
Risk Adjusted Return -22.75% N/A 38% 20.7% 26%
Market Capitalization 1.95B 0.11B 94% 0.36B 79%

5. Page 5 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio N/A 17.7 N/A 16.8 N/A
pbratio 0.7 1.9 83% 1.6 88%
pcfratio -3.6 -1.3 75% -0.2 67%
pfcfratio N/A 10.3 N/A 10.1 N/A
Management Effectiveness
retequity -8.84% -57.6% 76% -0.1% 42%
retinvcap -15.59% -39.6% 66% -0.6% 35%
retass -5.94% -17.1% 67% 0.0% 35%
debtequityratio N/A 35.2% N/A 32.3% N/A
Technical Ratios
yield N/A 13.2% N/A 2.6% N/A
sratio 8.34 4.49 16% 3.08 13%
spercent 19.88% 6.1% 7% 3.0% 9%
beta 1.98 1.12 17% 1.10 12%

6. Page 6 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
CGC:NSD (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 1st June, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Target Lowered by Canaccord Capital USD 6 » USD 4.5 2022-05-31
Target Lowered by CIBC Capital Markets USD 6.5 » USD 5 2022-05-31
Maintains Piper Sandler Underweight USD 6 » USD 4 2022-05-31
Target Down Stifel Nicolaus Research Sell USD 4 2022-05-30
Reiterates STA Research Hold USD 7 2022-05-30
Target Morningstar Buy USD 16 2022-05-30
Target Down Cowen Buy USD 5 2022-05-30
Reiterated by Cfra Hold USD 10 2022-05-28
Downgraded by Benchmark Hold » Sell 2022-05-27
Target Lowered by Alliance Global Partners USD 11 » USD 8 2022-05-20
Target Down Stifel Nicolaus Research Sell USD 4.5 2022-05-02
Target STA Research Buy USD 12 2022-03-23
Downgraded by Barclays
Equal Weight »
Underweight
2022-03-22
Maintains Barclays Equal-Weight USD 14 » USD 9 2022-03-01
Target Raised by Cantor Fitzgerald Securities USD 9.6 » USD 11 2022-02-18
Target Lowered by Canaccord Genuity USD 12 » USD 10 2022-02-10
Target Lowered by CIBC Capital Markets USD 12 » USD 9 2022-02-03
Target Lowered by Cantor Fitzgerald Securities USD 16.3 » USD 9.6 2022-01-28
Target Lowered by Alliance Global Partners Neutral » Neutral USD 18 » USD 11 2022-01-07
Downgrades Bank of America Underperform USD 19 » USD 10 2021-12-22
Downgraded by Piper Sandler Neutral » Underweight USD 11 » USD 7 2021-12-20
Initiates Coverage On Wells Fargo Underweight USD 8 2021-12-07
Downgraded by Eight Capital Neutral » Sell 2021-11-30
Target Lowered by Jefferies Financial LLC Positive » Hold USD 25.28 » USD 16.7 2021-11-23
Initiated by Barclays Equal Weight USD 14 2021-11-18

7. Page 7 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
CGC:NSD (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 1st June, 2022
Annual Financial (USD)

8. Page 8 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
CGC:NSD (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 1st June, 2022
Quarterly Financial (USD)

9. Page 9 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
CGC:NSD (Canopy Growth Corporation)
Drug Manufacturers-Specialty & Generic | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 1st June, 2022
Largest Industry Peers for Drug Manufacturers-Specialty & Generic
Symbol Company Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc +0.39 (+0.4%) USD 8.59B
MYL Mylan N.V N/A USD 8.59B
APHA Tilray, Inc N/A USD 6.86B
MNTA Momenta Pharmaceuticals, Inc N/A USD 6.24B
ITCI Intra-Cellular Therapies Inc -0.88 (-1.5%) USD 5.50B
PCRX Pacira BioSciences Inc -1.19 (-1.8%) USD 2.93B
TLRY Tilray Inc -0.06 (-1.3%) USD 2.26B
AMPH Amphastar Pharmaceuticals Inc -1.73 (-4.5%) USD 1.90B
IRWD Ironwood Pharmaceuticals Inc -0.11 (-1.0%) USD 1.72B
HCM HUTCHMED (China) Limited +0.96 (+10.0%) USD 1.65B
ETFs Containing CGC
Symbol Company Name Weight Mer Price(Change) Market Cap
CROP IQ Global Agribusiness Small C.. 0.00 % 0.76 % N/A USD 6.04M
MJ ETFMG Alternative Harvest ETF 0.00 % 0.75 % -0.09 (-1.2%) USD 0.49B
YOLO AdvisorShares Trust - AdvisorS.. 0.00 % 0.00 % +0.06 (+-1.2%) USD 0.09B
CNBS Amplify ETF Trust - Amplify Se.. 0.00 % 0.00 % +0.04 (+-1.2%) N/A
THCX The Cannabis ETF 0.00 % 0.00 % N/A N/A
MJJ MicroSectors Cannabis ETNs 0.00 % 0.00 % N/A N/A
MJO MicroSectors Cannabis 2X Lever.. 0.00 % 0.00 % N/A N/A
POTX Global X Funds - Global X Cann.. 0.00 % 0.00 % -0.04 (-1.2%) N/A
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%